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Summary
Despite current recommendations on the management of pre-operative anaemia, there is no pragmatic guidance for
the diagnosis and management of anaemia and iron deﬁciency in surgical patients. A number of experienced
researchers and clinicians took part in an expert workshop and developed the following consensus statement. After
presentation of our own research data and local policies and procedures, appropriate relevant literature was reviewed
and discussed. We developed a series of best-practice and evidence-based statements to advise on patient care with
respect to anaemia and iron deﬁciency in the peri-operative period. These statements include: a diagnostic approach
for anaemia and iron deﬁciency in surgical patients; identiﬁcation of patients appropriate for treatment; and advice
on practical management and follow-up. We urge anaesthetists and peri-operative physicians to embrace these rec-
ommendations, and hospital administrators to enable implementation of these concepts by allocating adequate
resources.
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Recommendations for best clinical
practice
1 Physicians should consider pre-operative anaemia
and iron deﬁciency as an indication for a peri-
operative care pathway that stretches from the
decision to operate until complete recovery from
surgery.
2 The presence of anaemia should be investigated in
all surgical procedures with expected moderate-to-
high blood loss (> 500 ml).
3 Serum ferritin level < 30 lg.l1 is the most sensi-
tive and speciﬁc test used for the identiﬁcation of
absolute iron deﬁciency. However, in the presence
of inﬂammation (C-reactive protein > 5 mg.l1)
and/or transferrin saturation < 20%, a serum fer-
ritin level < 100 lg.l1 is indicative of iron deﬁ-
ciency.
4 Major, non-urgent surgery should be postponed to
allow the diagnosis and treatment of anaemia and
iron deﬁciency.
5 When treating anaemia pre-operatively, the target
haemoglobin concentration should be ≥ 130 g.l1
in both sexes, to minimise the risk of transfusion-
associated unfavourable outcomes
6 Oral iron replacement should be targeted to
patients with iron deﬁciency with or without anae-
mia whose surgery is scheduled 6–8 weeks after
diagnosis, preferably by the primary care physician
(General Practitioner).
7 Daily (40–60 mg) or alternate-day (80–100 mg)
treatment with oral iron and nutritional advice
should be initiated immediately in patients with
iron deﬁciency and no contra-indications.
8 Sufﬁcient data exist to support intravenous iron as
efﬁcacious and safe. Intravenous iron should be
used as front-line therapy in patients who do not
respond to oral iron or are not able to tolerate it,
or if surgery is planned for < 6 weeks after the
diagnosis of iron deﬁciency.
9 The diagnosis and treatment of anaemia and iron
deﬁciency should commence as early as possible
in the peri-operative period, and ideally as soon as
the decision to undertake surgery is made.
Why was this consensus statement
developed?
Several guidelines for the management of peri-opera-
tive anaemia have been published over the last decade
[1–11]. However, for anaemia and iron deﬁciency in
adult surgical patients, there are a number of non-
evidence based misconceptions regarding prevalence,
consequences, diagnosis and treatment, as well as
inconsistency of terminology and lack of clear guid-
ance on clinical pathways. Throughout surgical
practice, there has been increased emphasis on
speed to operation, and many pre-assessment clinics
focus on the ability to facilitate same-day hospital
admissions, which may overlook potential opportu-
nities to optimise patients, and improve ﬁtness for
surgery.
How does this consensus statement
differ from other available guidelines?
There are a number of guidelines from professional
associations recommending ‘what to do’ [1–11]. The
aim of this document is to utilise the recommenda-
tions therein, and provide a working practice docu-
ment on ‘how to’ feasibly introduce these guidelines
into clinical practice; or better stated, how to do it.
Therefore, our goal is to provide independent, collec-
tive guidance and a pragmatic, clear clinical pathway
for the diagnosis and treatment of peri-operative iron
deﬁciency and anaemia in adult surgical patients, in
order to improve outcomes in a cost-effective manner.
Iron deficiency
Iron is the most common and widespread nutritional
deﬁciency, even in industrialised countries, and affects
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approximately two billion people worldwide [12, 13].
Iron deﬁciency, with or without anaemia, is associated
with chronic conditions such as cancer (43% across
different tumours), inﬂammatory bowel disease (45%),
chronic kidney disease (24–85%), chronic heart failure
(43–100%) and other chronic inﬂammatory diseases
[14].
Apart from its well-recognised role in erythro-
poiesis, iron is also a critical component in many
important cellular processes such as oxygen transport,
electron transfer reactions, mitochondrial respiration,
gene regulation and cellular immunity [15, 16]. Func-
tional iron deﬁciency in critically ill patients is associ-
ated with an increased duration of systemic
inﬂammatory response syndrome and prolonged ICU
stay [17]. In congestive heart failure, iron deﬁciency
has been independently associated with compromised
physical performance and quality of life [18], as well
as an increase in all-cause and cardiovascular mortality
[19]. Treatment of iron deﬁciency with i.v. iron may
improve functional status within 4 weeks, which has
been shown to be maintained after 24 and 52 weeks
[20, 21].
Importantly, in a large series of non-cardiac surgi-
cal patients (n = 2115; 48% women), the prevalence of
anaemia was 34%, and absolute iron deﬁciency and
iron sequestration (see below) was responsible for 75%
of the cases of anaemia (541/715) [22]. In addition,
before major orthopaedic or abdominal surgery, low
ferritin levels have been associated with increased rates
of postoperative infections [23, 24].
For a 70-kg man, total body iron is about
3500 mg (50 mg.kg1 body weight). Most of the iron
in the body is distributed in haemoglobin (Hb)
within red blood cell (65%; 2300 mg). Approximately
10% is found in muscle ﬁbres (in myoglobin) and
other tissues (in enzymes and cytochromes)
(350 mg). The remaining iron is stored in the liver,
macrophages and bone marrow (850 mg) [25]. The
amount of iron required for the daily production of
300 billion red blood cells (20–30 mg) is provided
mainly by macrophages recycling iron from senescent
red blood cells (RBC), while daily iron absorption
(1–2 mg) balances daily losses. Increased iron
requirements, limited external supply and increased
blood loss may lead to progressive iron deﬁciency
and, subsequently, iron deﬁciency anaemia [25]
(Table 1). Thus, different types (stages) of iron deﬁ-
ciency are found in surgical patients (Table 2), classi-
ﬁed as follows:
• Inadequate (low) iron stores; this refers to the body’s
inability to sustain erythropoiesis to recover from
blood loss at operation. This may be indicated by the
serum ferritin level; in a healthy adult, 1 ng.l1 fer-
ritin reﬂects approximately 8 mg stored iron [26].
As an example, a patient with a pre-operative ferritin
< 100 ng.l1 may not have enough iron reserves to
recover from a 30–40 g.l1 Hb drop, while main-
taining normal iron stores (ferritin > 30 ng.l1).
• True (absolute) iron deﬁciency without anaemia
refers to a reduction in total body iron with normal
Hb, as levels of erythroid iron are still sufﬁcient for
erythropoiesis. This condition is often seen in
women of child-bearing age.
• Iron deﬁciency anaemia refers to a more severe
condition in which decreased iron stores result in
decreased Hb and usually microcytic hypochromic
red cells (mean corpuscular volume < 80 ﬂ; mean
corpuscular haemoglobin < 27 pg). The corrected
Table 1 Main causes of iron deﬁciency.
A. Increased demand
• Growth during infancy and childhood
• Treatment with erythropoiesis-stimulating agents
B. Limited supply
• Poor intake
• Inappropriate diet with deficit in bioavailable iron and/
or ascorbic acid
• Malabsorption
- Gastric resection
- Helicobacter pylori infection (even without signifi-
cant bleeding)
- Malabsorption syndromes (Crohn’s disease and celiac
disease)
• Drug interference (gastric anti-acid agents and antise-
cretory drugs)
C. Increased losses
• Phlebotomy
- Blood donation
- Dialysis (particularly haemodialysis)
• Haemorrhage
- Surgery
- Trauma
- Gastrointestinal bleeding
- Genitourinary bleeding
- Respiratory tract bleeding
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reticulocyte count provides an estimate of the rate
of effective marrow production compared with nor-
mal (set as a production index of 1). A production
index greater than 2 is not compatible with iron
deﬁciency anaemia.
• Functional iron deﬁciency: this refers to insufﬁcient
mobilisation of iron from stores due to increased
demands, in the presence of normal or elevated
iron stores. It is clearly deﬁned in renal patients
following treatment with erythropoiesis-stimulating
agents [15].
• Iron sequestration: this refers to decreased iron
mobilisation from the stores in the liver and the
macrophages to meet daily bone marrow require-
ments. This is caused by inﬂammation, which up-
regulates hepatic hepcidin synthesis and may
decrease the synthesis and activity of erythropoetin.
Hepcidin binds to ferroportin, the only known
iron-exporting protein in humans, and promotes
its internalisation and degradation, resulting in
inhibition of intestinal iron absorption and iron
sequestration at liver and macrophages [25]
(Fig. 1). This may evolve to true iron deﬁciency in
patients with inﬂammation and chronic blood
losses.
Diagnosis of iron deficiency
Serum ferritin and transferrin saturation (TSAT) are
commonly used for an initial evaluation of iron sta-
tus. Serum ferritin level is the most widely-used test
for evaluating iron stores, while TSAT reﬂects iron
availability for erythropoiesis (TSAT < 20% indicates
insufﬁcient iron supply to support normal erythro-
poiesis). C-reactive protein (CRP) is a marker of
inﬂammation which is useful when iron-restricted
erythropoiesis due to iron sequestration is suspected
[25, 26]. Thus:
• A serum ferritin level < 30 lg.l1 is the most sensi-
tive (92%) and speciﬁc (98%) cut-off level for the
identiﬁcation of true iron deﬁciency (with or with-
out anaemia); no further laboratory work-up is
needed (Fig. 2) [15, 25, 27].
Table 2 Characteristics of the different stages of iron deﬁciency in surgical patients.
Iron status Laboratory findings Initial treatment Adjuvant treatment
Normal Ferritin 30–300 lg.l1
TSAT 20–50%
CRP < 5 mg.l1
None None
Low iron stores (for surgery
with moderate-to-high
blood losses)
Ferritin < 100 lg.l1 Low dose oral iron
(40–60 mg iron per day or
80–100 mg alternate days,
6–8 weeks)
Intravenous iron,
if intolerance, contraindication or no
response to oral iron or short time
to surgery
Iron deficiency Ferritin < 30 lg.l1 Low dose oral iron
(40–60 mg iron per day or
80–100 mg alternate
days, 6–8 weeks)
Gastro-intestinal/urological investigations
Intravenous iron,
if intolerance, contraindication or no
response to oral iron or short time to
surgery
*Ferritin 30–100 lg.l1
TSAT < 20% and/or
CRP > 5 mgl1
Intravenous iron
(Calculated dose)†
Treat underlying chronic disease if
possible
Recombinant erythropoietin in the
selected case
if anaemia does not respond to i.v. iron
alone
Functional iron deficiency* Ferritin 100–500 lg.l1
TSAT < 20%
Intravenous iron
(Calculated dose)†
Revise erythropoietin dose
Check folic acid and vitamin B12
Iron sequestration* Ferritin > 100 lg.l1
TSAT < 20% and/or
CRP > 5 mg.l1
Recombinant erythropoietin,
if anaemia
Intravenous iron,
if functional iron deficiency develops
CRP, C-reactive protein; Fe, elemental iron; TSAT, transferrin saturation index.
*Low reticulocyte Hb content (CHr < 28 pg), high proportion of hypochromic red cells (HYPO > 5%), low RBC size factor
(RBCSF < 88 ﬂ) or ferritin index > 2 will conﬁrm a component of iron deﬁciency.
†Total iron deﬁciency [mg] = (Target Hb  Baseline Hb [g.l1])  0.24  Body weight [kg] + 500. A simpliﬁed calculation is
200 mg per each 10 g.l1 of Hb deﬁcit respect to target Hb + 500 mg for stores.
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• In the presence of inﬂammation (CRP > 5 mg.l1),
and/or TSAT < 20%, ferritin < 100 lg.l1 strongly
suggests iron deﬁciency (see below) (Fig. 2). It also
indicates inadequate iron stores for surgery during
which moderate-to-high blood loss is expected.
• In contrast, TSAT < 20% and ferritin > 100 lg.l1
usually indicates iron sequestration, as seen in
inﬂammatory conditions (CRP > 5 mg.l1), or
functional iron deﬁciency, as seen during treatment
with erythropoiesis-stimulating agents (Table 1;
Fig. 2) [25].
However, although ferritin values > 100 lg.l1
argue against concurrent true iron deﬁciency in the
setting of inﬂammation, due to its acute phase reactiv-
ity, its diagnostic value is imperfect. Other tests, such
as low reticulocyte Hb content (CHr < 28 pg) or an
increase in hypochromic red cells (Hypo > 5%), can
be utilised to evaluate for a component of iron deﬁ-
ciency, which if present suggests iron supplementation
may be beneﬁcial [25, 28]. The ratio of serum transfer-
rin receptor level to the log of ferritin (sTfr/log Ft),
the so-called ferritin index, may be used when these
automated red cell parameters are not routinely avail-
able [25, 28]. A ferritin index > 2 indicates true iron
deﬁciency, and is a strong predictor of response to i.v.
iron [28, 29]. Detailed information regarding the
advantages, disadvantages, limitations and diagnostic
values of these parameters can be found elsewhere
[30].
Anaemia
Anaemia is deﬁned by the World Health Organization
as an Hb concentration < 130 g.l1 for men,
< 120 g.l1 for non-pregnant women and < 110 g.l1
for pregnant women [31]. These deﬁnitions are widely
quoted and accepted, and are used in most epidemio-
logical studies. They are also adopted in most blood
conservation guidelines, where no further laboratory
work-up is deemed necessary for non-anaemic
patients.
However, we consider that this may not be reliable
for the classiﬁcation of non-pregnant women undergo-
ing surgical procedures in which moderate-to-high
blood loss is expected. Women have lower circulating
blood volumes than men, but the same procedures
performed in either sex often result in comparable
amounts of blood loss. Therefore, when measured as a
proportion of circulating blood volume, blood losses
are proportionally higher in women and may result in
higher transfusion rates, as corroborated by a study in
orthopaedic surgery [32] and the ﬁrst Austrian bench-
mark study [33]. As women with a pre-operative Hb
of 120 g.l1 are twice as likely to require a transfusion
as men with an Hb of 130 g.l1, this Hb level should
be considered as suboptimal in surgical settings. In
Immune system 
activation
Erythrocytes Macrophages Small bowel
Kidney
Bone marrow
↓EPO
IFNγ, TNFα, 
IL1β, IL-6 Liver
↑Hepcidin
↓Fe-Tf-Fe
Stimulation
Inhibition
Figure 1 Effects of inﬂammation on iron metabolism and erythropoiesis. 1, release of immune and inﬂammatory
cytokines; 2, decreased erythropoietin (EPO) production; 3, decreased erythropoietic stimulation; 4, inhibition of ery-
throid cell proliferation; 5, augmented erythrophagocytosis; 6, IL-6 induced hepcidin release; 7 & 8, decreased ferro-
portin-mediated release of iron from enterocytes (inhibition of iron absorption) and macrophages (iron
sequestration), leading to decreased transferrin-bound iron; 9, decreased iron availability for erythropoiesis.
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cardiac surgery, a 10 g.l1 decrease in Hb has been
shown to be independently associated with increased
transfusion requirements, increased mortality and pro-
longed hospital stay [34].
Consequently, apart from replenishing iron
stores, pre-operative treatment of iron deﬁciency
anaemia should be aimed at producing a target Hb
level ≥ 130 g.l1 in both sexes, to minimise the risk
of transfusion-associated unfavourable outcomes [35].
Patients who are anaemic and require major sur-
gery (including the obstetrics and gynaecology popula-
tion), especially if moderate to high blood loss
(> 500 ml) is likely and/or if there is a ≥ 10% statisti-
cal probability for red blood cell (RBC) transfusion,
should be investigated (Fig 3). Laboratory investiga-
tions should be performed as early as possible in the
pre-operative period in order to implement the most
appropriate treatment, if needed. They should initially
include at least full blood count, serum ferritin, TSAT,
a marker of inﬂammation (e.g. serum CRP) and a
marker of renal function (e.g. serum creatinine), which
can be easily requested by a surgeon (at the time of
listing for surgery), an anaesthetist (during the pre-
anaesthesia assessment) or a primary care physician/
general practitioner. In some hospitals, there is also
the possibility of automatically ordering additional lab-
oratory tests when an Hb < 130 g.l1 is detected by
pre-operative analysis.
Intervening to treat pre-operative iron deﬁciency
anaemia in the surgical patient can be expected to
reduce the number of transfusions given and thereby
improve outcomes, even in those for whose anaemia,
surgery is the cure. There is good evidence that
attempts to correct iron deﬁciency anaemia pre-opera-
tively will improve Hb before surgery, but there is little
good quality evidence that it can modify the excess of
risk for postoperative complications, other than those
associated with transfusion [28, 36–42]. However,
moderate to severe anaemia (Hb < 110 g.l1) results
in worse outcomes than milder anaemia [43]. In con-
trast, there is also good evidence that correcting anae-
mia by transfusing blood can be detrimental to the
outcomes of surgery [37, 44, 45].
Despite the lack of level-one evidence for
improved outcomes, it is still recommended as good
clinical practice to treat all surgical patients with pre-
operative iron deﬁciency anaemia, but with a particular
emphasis on treating those undergoing major surgery.
Patients undergoing more minor surgical procedures
are unlikely to see wide ﬂuctuations in Hb postopera-
tively, and surgery can proceed while anaemia evalua-
tion and treatment is ongoing.
Patients who have absolute iron deﬁciency should
also be investigated for gastro-intestinal pathology
(Table 1). The prevalence of other haematinic deﬁcien-
cies before elective major orthopaedic surgery is
Endocrine RenalUnknow cause DrugsMalignancy
Other
anaemiasNormal
Megalobastic
anaemia
Low
Vitamin B12
Folate
Iron deficiency
anaemia
Anaemia of chronic
inflammation with
iron deficiency
Anaemia of chronic
inflammation
Normal
Ferritin < 30 mg.l–1
Ferritin 30–100 mg.l–1
+ transferrin saturation < 20% 
or C-reactive protein > 5 mg·l–1
Ferritin >100 mg.l–1
+ transferrin saturation < 20% 
or C-reactive protein > 5 mg.l–1
Altered
Hb < 130 g.l–1 Iron
tests
Figure 2 Algorithm for classiﬁcation of peri-operative anaemia.
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approximately 12% for vitamin B12 [deﬁned by serum
concentration < 270 pg.ml1 (200 pmol.l1)], and 3%
for folate [deﬁned by serum concentration < 3 ng.ml1
(5 nmol.l1)] [46]. If none are found, other causes of
anaemia should be ruled out (Fig. 2).
Treatment
Treatment of pre-operative iron deﬁciency anaemia
should be implemented as early as possible before the
scheduled surgical procedure. Most major surgery is
elective. In the UK, the recent NHS Blood and Trans-
plant audit showed there was a median of 60 days
from listing the patient for surgery to the operation
itself (http://hospital.blood.co.uk/audits/national-com-
parative-audit/). Thus, treatment of iron deﬁciency
anaemia should be attempted while the patient is on
the surgical waiting list, although this is currently
rarely practised [47].
Regarding oral iron, in non-anaemic iron-deﬁcient
women, high doses of iron sulphate stimulate hepcidin
release, which results in lower iron absorption from
the next daily dose [48]. In contrast, it appears that
low-dose (≤ 60 mg) oral iron given on alternate days
may maximise fractional iron absorption, increase
dosage efﬁcacy, reduce gastro-intestinal exposure to
unabsorbed iron and ultimately improve tolerance and
adherence to treatment [48]. As anaemia-induced
hypoxia and erythropoietin production downregulate
the expression of hepcidin [15, 25], this may counter-
balance the stimulatory effect of iron. In octogenarian
patients with iron deﬁciency anaemia, 50 mg or
150 mg iron sulphate daily for 2 months both
improved Hb and ferritin levels equally, but fewer
side-effects were observed with the lower dose [49].
Therefore, when the interval before surgery is sufﬁcient
(at least 6–8 weeks) and no contra-indications are pre-
sent, daily (40–60 mg) or alternate-day (80–100 mg)
supplementation with oral iron and nutritional advice
may be appropriate. The actual dose may depend upon
the elemental iron content of the available oral iron
Listed for surgery
Transfusion risk > 10% and/or estimated blood loss > 500 ml ?
NO YES
Standard pre-
operative
evaluation1
Proceed
to surgery
Pre-operative Hb < 130 g.l–1 ?
NO YES
Is there haematinic
deficiency?3
NO YES
Proceed to surgery
Prescribe 
supplements
Non-elective
Surgery4
Classify anaemia 
and start
treatment5
Proceed
to surgery
Elective
surgery
Classify anaemia 
and start
treatment5
Postpone surgery
until patient no 
longer anaemic
Laboratory work-up request2
Figure 3 Algorithm for the management of a surgical patients. 1, According to centre protocol for each surgical pro-
cedure; 2, It should initially include at least full blood counts, serum ferritin, transferrin saturation, a marker of
inﬂammation (e.g. serum C-reactive protein) and a marker of renal function (e.g. serum creatinine); 3, Haematinic
deﬁciencies are deﬁned by ferritin < 100 lgl1, vitamin B12 < 270 pgml1 and/or folate < 3 pgml1; 4, Including
patients presenting late before surgery and non-deferrable surgery (e.g. cancer surgery); 5, According to algorithm
depicted in Fig. 2.
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formulation, which differs depending on country of
manufacture.
However, many patients will not respond to oral
iron, especially those with functional iron deﬁciency
and chronic illness or infection and those with ongo-
ing blood loss [15, 25]. Others will not tolerate oral
iron due to gastro-intestinal side-effects. Once oral
iron has been commenced, the Hb should be measured
again, at least 4 weeks before surgery. In the absence
of an increased Hb or if the patient is intolerant, i.v.
iron is the preferred replacement route. If surgery is
planned in less than 6 weeks time, i.v. iron may also
be the most effective option.
Intravenous iron is highly efﬁcacious at replenishing
iron stores and increasing Hb in anaemia due to iron
deﬁciency with or without inﬂammation (Fig. 2). The
dose of i.v. iron may be calculated from the baseline and
target Hb and patient’s body weight, adding 500 mg for
iron stores (in patients > 35 kg) [25]. In practice, a dose
of 1000–1500 mg is sufﬁcient in most surgical patients
and can usually be given by slow infusion over less than
1 h in one sitting or in two divided doses, depending on
the preparation used. Most patients feel better in 3 days,
with a rapid Hb response (50% at 5 days, 75% at 10–
14 days, maximal at 3 weeks) [50].
In a small series, i.v. iron sucrose before orthopae-
dic surgery has been shown to be useful for treating
iron deﬁciency anaemia, with a maximum effect on
Hb after 2 weeks [51]. In abdominal surgery, i.v. iron
carboxymaltose (1000 mg) 2–4 weeks [40, 42] or 8–
10 days pre-operatively [41] has been shown to
decrease RBC transfusion and hospital stay.
Intravenous iron treatment < 2 weeks pre-opera-
tively has also been shown to be successful in decreas-
ing the need for RBC transfusion, acute kidney injury,
hospital stay and infections in orthopaedic and cardiac
surgery [52, 53]. A quicker recovery in Hb postopera-
tively was also observed in iron-deﬁcient patients trea-
ted with i.v. iron sucrose [54] or carboxymaltose [41,
42]. Administration of i.v. iron isomaltoside (1000 mg)
1 day before or even on the day of surgery can
improve postoperative Hb recovery even in non-anae-
mic patients without iron deﬁciency [55].
Presently, there is a lack of high-quality data about
effect on outcomes, but a number of large randomised,
controlled trials are in progress [56].
Iron deficiency without anaemia
A recent meta-analysis of 21 trials in different clinical
settings concluded that there is emerging evidence that
non-anaemic iron deﬁciency is a disease in its own
right, deserving of further research in the development
of strategies for detection and treatment [57]. Non-
anaemic patients with iron deﬁciency or inadequate
iron stores undergoing surgical procedures with
expected moderate-to-high blood loss may beneﬁt from
pre-operative iron administration, to boost recovery
from postoperative anaemia [1, 3] (Fig. 2). In those
with absolute iron deﬁciency (ferritin < 30 lg.l1), the
need for gastro-intestinal investigations should be con-
sidered [3]. Microcytosis due to iron deﬁciency without
anaemia should be evaluated for chronic hypoxaemia,
myeloproliferative disease (e.g. polycythaemia rubra
vera), or another cause of increased red cell production.
Iron replacement may cause a surge in Hb that could
induce hyperviscosity in this subgroup.
In non-anaemic orthopaedic surgical patients, the
administration of iron ferrous sulphate and vitamins
during the weeks preceding surgery has been shown to
increase serum ferritin and transferrin saturation [58]
and reduce transfusion [59]. However, adherence to
iron supplementation was 67%, and adverse drug reac-
tions were present in 52% of patients [60].
In women undergoing major non-cardiac surgical
procedures, the prevalence of true iron deﬁciency (fer-
ritin < 30 lg.l1) for Hb 120–129 g.l1 was similar to
that for Hb < 120 g.l1, and signiﬁcantly higher than
for Hb ≥ 130 g.l1 (42%, 51% and 24%, respectively;
p < 0.05). This also applies to insufﬁcient iron supply
for erythropoiesis, as deﬁned by TSAT < 20% (58%,
69% and 34%, respectively; p < 0.05) [22]. Thus,
although considered as non-anaemic according to
WHO deﬁnitions [31], most women with Hb 120–
129 gl1 would beneﬁt from iron replacement ther-
apy, for optimising pre-operative Hb levels and facili-
tating recovery from postoperative anaemia.
For non-anaemic patients undergoing surgery with
a high risk for developing severe postoperative anaemia,
we suggest the administration of oral iron. Intravenous
iron administration (e.g. 500 mg) should be considered
if surgery is scheduled to take place in < 4 weeks or if
the patient cannot tolerate oral iron [1].
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Delaying surgery
As stated above, uncorrected pre-operative anaemia is
a risk factor for poor outcome [61–66]. Although there
is little evidence currently that treatment of iron deﬁ-
ciency anaemia improves outcome [60, 67], it does
reduce transfusion and may reduce hospital stay. Con-
sequently, there is considerable uncertainty as to
whether surgery should be delayed in patients with
undiagnosed/untreated anaemia.
The problem may be divided into patients under-
going surgery for benign vs. malignant disease. In
major surgery for benign disease, especially when
blood loss > 500 ml is expected or possible, patients
should be informed about the relationship between
anaemia, morbidity and mortality, and should be given
the opportunity to postpone non-urgent surgery until
their anaemia is investigated and treated [4, 35]. Sev-
eral guidelines recommend postponing the operation
for about 4 weeks to allow appropriate management of
anaemia [1, 2, 4, 8].
In some European countries, the allowable time
between diagnosis and surgery for malignant disease is
subjected to legal regulations. Nevertheless, many
receive pre-operative adjuvant therapy, which allows
sufﬁcient time for concurrent treatment of pre-opera-
tive iron deﬁciency anaemia.
Postoperative anaemia
Anaemia is present in up to 90% of patients in the
immediate postoperative period after major surgery
[68]. The main causes are: presence of pre-operative
anaemia; peri-operative blood loss; poor nutritional
intake in the postoperative period; and frequent blood
sampling for laboratory tests. In addition, increased
hepcidin due to the inﬂammatory response to surgery
can lead to inhibition of iron absorption from the
small bowel and reduced iron release from stores (iron
sequestration) [25] (Fig. 1). These effects can last for a
few weeks after major surgery and aggravate postoper-
ative iron deﬁciency anaemia.
Recently, the National Institute for Clinical Excel-
lence [69] and other international guidelines [4, 5, 70]
have reduced the transfusion thresholds for surgical
patients to 70 g.l1 (80 g.l1 for patients with a history
of ischaemic heart disease) in the absence of active
bleeding. This change in practice has led to more
patients being discharged with signiﬁcant anaemia
after major surgery. Therefore, it is important to
implement strategies for postoperative anaemia man-
agement.
Management of iron deﬁciency with oral iron in
the immediate postoperative period has a very limited
role due to poor absorption and considerable side-
effects, and is not recommended [4]. In contrast, i.v.
iron has been successfully used to treat iron deﬁciency
anaemia after surgery for lower limb arthroplasty [71],
gastrectomy [72] and postpartum haemorrhage [73].
The administration of a single 1000-mg dose of ferric
carboxymaltose after major orthopaedic surgery,
abdominal and genito-urinary surgery, and others, has
been shown to correct anaemia and improve quality of
life compared with oral iron [74, 75].
Transfused packet RBC contains haem iron (200–
250 mg per unit), plus a small amount of labile iron
which is immediately available for erythropoiesis; in
part, dependent on the storage time of the transfused
RBC unit [76]. After transfusion, the patient’s Hb is
usually < 10 g.l1. Correcting postoperative iron deﬁ-
ciency, in addition to RBC transfusion to raise Hb,
may be important to improve function, as shown in
animal models [77]. Further research is required as to
whether supplemental iron given to correct iron deﬁ-
ciency in patients who are transfused peri-operatively
is beneﬁcial in humans.
Safety of i.v. iron therapy
Currently, six i.v. iron formulations are available in the
USA and/or Europe (Table 3), and serious adverse
events (SAEs) are very rare (38 per 106 administrations;
deaths, 0.4 per 106 administrations) [78]. In contrast, the
most recent Serious Hazards of Transfusion Report in
the UK quotes the risk of death related to transfusion as
1 in 100,000, and the risk of major morbidity as 1 in
16,000 [79]. The European Medicines Agency concluded
that the beneﬁts of i.v. iron exceed the risks when used
appropriately (correct indication and dose), without any
difference in safety proﬁle among available formulations
[80]. In line with these recommendations, guidance for
risk minimisation and management of hypersensitivity
reactions to i.v. iron has been recently published [81].
© 2016 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists of Great Britain and Ireland 241
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Some patients who receive i.v. iron may exhibit
complement activation-related pseudo-allergy, which
should not be misinterpreted as hypersensitivity. This
occurs in approximately 1:200 iron-treated patients,
and can consist of arthralgia, myalgia or ﬂushing, but
without associated hypotension, tachycardia, tachyp-
noea, wheezing, stridor or peri-orbital oedema [82].
Symptoms abate without intervention, and the patient
may be rechallenged or another i.v. iron formulation
tried [82].
A recent meta-analysis of 103 trials published
from 1965 to 2013 (including 19,253 patients) con-
cluded that i.v. iron therapy was not associated with
an increased risk of serious adverse events or infection
when compared with oral or intramuscular iron, no
iron or placebo [83]. In large observational studies,
peri-operative i.v. iron did not negatively impact on
rates of transfusion, infection and 30-day mortality in
surgical patients [51, 84]. In contrast, red cell transfu-
sion delivers haem and labile iron which supports bac-
terial growth more readily [85].
The preponderance of published evidence indi-
cates that i.v. iron is safe, supporting a greater and
earlier role for treating iron deﬁciency and raising the
question of whether parenteral iron should be consid-
ered for front-line therapy in conditions where oral
iron will predictably fail. However, further prospective
efﬁcacy and safety trials in various surgical settings
are required to make evidenced-based conclusions
[82].
Cost implications of iron therapy
There are few studies that have undertaken formal
cost–beneﬁt analysis of iron treatment. Bhandari et al.
[86] performed a comparative analysis of the costs of
administering i.v. iron formulations against RBC trans-
fusion, by considering acquisition costs plus adminis-
tration costs (nursing time and giving sets) and
transportation to hospital, across three dosage levels
(600 mg, 1000 mg and 1600 mg). At all doses, i.v. iron
resulted in a net saving when compared with RBC
transfusion, with the biggest differences observed for
ferric carboxymaltose and iron isomaltoside-1000.
Calvet et al. [87] compared the cost implications
of ferric carboxymaltose vs. iron sucrose vs. oral iron
for avoiding red cell transfusion in 282 patients with
colorectal cancer and anaemia, using cost-minimisation
analysis. Direct and indirect costs for acquisition and
administration of iron product and RBC concentrates,
as well as hospitalisation costs, were included in the
cost model. Ferric carboxymaltose reduced hospital
stay by 2.3 days compared with iron sucrose and by
2.6 days compared with oral iron, resulting in cost
savings of £437 (485€, $532) and £245 (274€, $300)
per patient, respectively.
Data from 182 matched pairs of total lower limb
arthroplasty patients, managed with a restrictive trans-
fusion protocol and without (control) or with postop-
erative i.v. iron, were retrospectively reviewed [88].
Acquisition and administration costs of iron (600 mg
iron sucrose or ferric carboxymaltose) and RBC con-
centrates, Hb, and prolonged stay in hospital were
used. Patients receiving RBC transfusion stayed in hos-
pital longer (1.9 days [95% CI 1.2–2.6]). Compared
with control, i.v. iron reduced RBC transfusion rate
(11.5% vs. 26.4%) without incremental cost [88].
Thus, the use of newer i.v. iron formulations
(e.g. iron isomaltoside 1000 or ferric carboxymaltose)
allows the rapid administration of larger single doses
(≥ 1000 mg), and are more convenient both for
the patient (e.g. fewer hospital visits, less time off
work) and the health system (e.g. less visits to day
hospital, less ambulance transfers, less total cost) [40,
86–89].
When comparing i.v. iron with other interven-
tions implemented to reduce blood transfusion and/
or placebo, it would be interesting to include the
costs of postoperative complications and other clini-
cal endpoints as well. Anaesthetists and surgeons
should consider pre-operative iron deﬁciency not as
a single ‘point’, although its treatment is essential.
Instead, this should trigger a peri-operative bundle of
care, known as Patient Blood Management, started at
the time that surgery is booked and carried on until
full recovery from the surgical intervention has
occurred. This should be planned and documented
pre-operatively, both in urgent and elective patients
[90–92]. We believe there is ample evidence to sup-
port peri-operative blood management within the
context of an evidence-based enhanced recovery
programme to secure optimal interpretation of the
intervention [93].
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